Navigation Links
Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
Date:7/31/2009

CHICAGO, July 31 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced that it received a complete response letter today from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Restanza(TM) (cethromycin) for the outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP). In its letter, the FDA indicated that they cannot approve the application for Restanza in its current form and that, to gain approval, additional clinical data is required to demonstrate efficacy. Advanced Life Sciences submitted the NDA in September, 2008 based on the results of 53 clinical studies including 2 pivotal Phase 3 studies in CAP and a safety database of over 5,000 patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

Advanced Life Sciences intends to comply with the Agency's recommendations and continue to pursue approval of Restanza in CAP. The Company believes that an additional well-controlled clinical study designed to demonstrate efficacy in a more severe CAP population will likely be required for the approval of Restanza. In parallel, the Company will continue to advance Restanza as a biodefense agent against anthrax, plague and tularemia.

On June 2, 2009, the FDA Anti-Infective Drugs Advisory Committee (AIDAC) reviewed the Restanza NDA. The AIDAC voted that Restanza demonstrated safety for the outpatient treatment of adults with mild-to-moderate CAP, but voted that Restanza did not demonstrate efficacy in the treatment of CAP. The committee's negative vote on the drug candidate's efficacy followed a discussion that the Restanza NDA included data on patients with mild-to-moderate disease and that the new draft guidance for developing treatments for CAP, released in March, 200
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/20/2014)... Virginia (PRWEB) October 20, 2014 ... NDA Partners LLC, announced today that Ellen Teplitzky, ... legal support for the pharmaceutical industry, has joined ... manager of its legal services practice. NDA ... and expert witness and testimony, to top law ...
(Date:10/19/2014)... 20, 2014 OCTOBER 20-22, ... (ABIM). ABIM will take place at ... about ABIM 2014 is now available at ... representing companies and organizations from all over ... information on the latest products and developments ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... MATK ) announced that it intends to release the results ... 2008, at approximately 4:00 p.m. Eastern Time (ET). Following the ... to discuss these results with investors. All interested parties may ... site at http://investors.martek.com . , , ...
... -- Tianyin,Pharmaceutical, Co., Inc., (NYSE EuroNext: TPI), a ... based in Chengdu, China,today announced the implementation of ... distributors and hospital clients into three classes in ... The new ...
... MD, FACS, as Principal Investigator , , ... Inc. (Nasdaq: DCTH ) announced today that ... Medical Center (UPMC), has joined Delcath,s Phase III clinical ... metastatic melanoma in the liver. James Pingpank, MD, FACS, ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 2Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 3Delcath Adds University of Pittsburgh Medical Center to Phase III Trial 2Delcath Adds University of Pittsburgh Medical Center to Phase III Trial 3Delcath Adds University of Pittsburgh Medical Center to Phase III Trial 4
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... commerce market releases photos and video of the recent opening bell ... th . Gino Pereira , CEO of ... Mr. Chad A. Verdi rang the bell.  ... and employees "for their work and dedication in bringing the world,s ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... a new kind of stem cell that can become either ... vessels, according to a study published today in the journal ... cell type contradicts current theory on how organs arise from ... origins of, and future treatment for, liver cancer., Thanks to ... complex being made up of more than 200 cell types. ...
Breaking Biology News(10 mins):Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... November 2, 2010 CONRAD, leaders in reproductive health ... from the US Agency for International Development (USAID). The ... are contraceptive and also prevent HIV and STI infections. ... of tenofovir gel, conducted by the Centre for Programme Research ...
... Please credit the journal or the American Chemical Society as ... For the first time in the United States, researchers ... Bisphenol A (BPA) in fresh and canned food as well ... limited sample, however, were almost 1,000 times lower than the ...
... knows better "The Promise of Human Genetics" than the man ... D.C. on Wednesday: this year,s Gruber Genetics Prize recipient Prof. ... "grow" genes in yeast, thus allowing scientists to create and ... cells inherit information. It is Fink whose "transforming" technique effectively ...
Cached Biology News:USAID awards $5 million to CONRAD 2Fink receives Gruber Genetics Prize, lectures at American Society of Human Genetics annual meeting 2
... The ISOQUANT(R) Isoaspartate Detection Kit is intended ... in proteins and peptides, which can result ... or rearrangement of aspartic acid residues during ... not depend on the monitoring of charge ...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Rabbit polyclonal to EDG2 ( Abpromise for all tested applications). entrezGeneID: 1902 SwissProtID: Q92633...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Biology Products: